These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8893882)

  • 1. Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Burkes RL; Cormier Y; Crump M; Feld R; Strack T; Schulz M
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):48-54. PubMed ID: 8893882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
    Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T; Schulz M
    J Clin Oncol; 1996 May; 14(5):1656-62. PubMed ID: 8622085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
    Bourgeois H; Billiart I; Chabrun V; Chieze S; Lemerre D; Germain T; Ferrand V; Meurice JC; Daban A; Tourani JM
    Am J Clin Oncol; 2004 Feb; 27(1):89-95. PubMed ID: 14758140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report.
    Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T
    Lung Cancer; 1996 Feb; 14(1):135-44. PubMed ID: 8696717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study.
    Lippe P; Tummarello D; Monterubbianesi MC; Silva RR; Giuliodori L; Mari D; Santo A; Pasini F; Cetto GL; Rossi D; Porfiri E; Cascinu S; Cellerino R
    Ann Oncol; 1999 Feb; 10(2):217-21. PubMed ID: 10093692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
    Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
    Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Kocijancic I; Segedin B; Vrankar M
    Anticancer Drugs; 2005 Nov; 16(10):1129-34. PubMed ID: 16222156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
    Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Villalona-Calero MA; Ritch P; Figueroa JA; Otterson GA; Belt R; Dow E; George S; Leonardo J; McCachren S; Miller GL; Modiano M; Valdivieso M; Geary R; Oliver JW; Holmlund J
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6086-93. PubMed ID: 15447994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study.
    Steward WP; Dunlop DJ; Cameron C; Talbot DC; Kleisbauer JP; Thomas P; Guerin JC; Perol M; Sanson C; Dabouis G
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():33-7. PubMed ID: 8718423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
    Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
    Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
    Zwitter M; Kovac V; Smrdel U; Vrankar M; Zadnik V
    J Thorac Oncol; 2009 Sep; 4(9):1148-55. PubMed ID: 19546818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
    Castellano D; Lianes P; Paz-Ares L; Hidalgo M; Guerra JA; Gómez-Martín C; Gómez H; Calzas J; Cortés-Funes H
    Ann Oncol; 1998 Apr; 9(4):457-9. PubMed ID: 9636840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
    Antón A; Díaz-Fernández N; González Larriba JL; Vadell C; Masutti B; Montalar J; Barneto I; Artal A; Rosell R
    Lung Cancer; 1998 Nov; 22(2):139-48. PubMed ID: 10022221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. A pilot study.
    Lippe P; Silva RR; Giuliodori L; Cancellieri MA; Battelli N; Massacesi C; Berardi R; Bisonni R; Gesuita R; Cellerino R
    Minerva Med; 2000; 91(3-4):53-7. PubMed ID: 11037630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
    Crinò L; Scagliotti G; Marangolo M; Figoli F; Clerici M; De Marinis F; Salvati F; Cruciani G; Dogliotti L; Pucci F; Paccagnella A; Adamo V; Altavilla G; Incoronato P; Trippetti M; Mosconi AM; Santucci A; Sorbolini S; Oliva C; Tonato M
    J Clin Oncol; 1997 Jan; 15(1):297-303. PubMed ID: 8996156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
    Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
    J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.